DoseMe Unveils New Analytics User Interface to Power the Future of Data-Driven Precision Dosing
In this article:
New interface sets the stage for continued expansion of DoseMe’s technology platform, analytics expansion, and innovative dosing models
Jupiter, FL – May 15, 2025
DoseMe, a leading provider of Bayesian model-informed precision dosing (MIPD), today announced the launch of a new analytics user interface, designed to deliver a more intuitive experience and lay the foundation for continuous innovation in data analytics.
This update is more than just a visual upgrade. It introduces a modernized infrastructure that enhances performance, improves clarity, and prepares the Analytics suite for rapid feature development, ultimately enabling clinicians to gain faster, clearer, and more actionable insights.
“We’re committed to helping clinical teams make confident, data-driven decisions and have regular exciting additions and updates to the analytics package based on continued customer feedback, » said Sharmeen Roy, PharmD, BCPS, chief science and strategy officer at DoseMe. « This analytics refresh is a major step forward in our journey to provide the tools clinicians need to optimize care and drive precision.”
While the core workflows and dashboards remain unchanged, users will benefit from a newly streamlined, responsive environment designed to simplify navigation and accelerate access to insights. Key enhancements include:
- Faster Load Times: Significantly faster load speed to help users access key clinical and operational data more efficiently.
- Streamlined Dashboard Navigation: A new tabbed structure organizes dashboards into Clinical Statistics, Drug Model Usage, and Platform Usage, making it easier to find and use the most relevant reports.
- Real-Time Insights on Dosing Practices: Continuously track outcomes and dosing trends using your existing dashboards, now grouped more intuitively.
- Improved Data Clarity: Complex dosing metrics are now presented in a clearer, more accessible format to support quicker interpretation.
Contact DoseMe’s support team at sales@dosemehealth.com to answer any questions or assist with the transition.
Additional Resources
Connect with DoseMe on LinkedIn
Follow DoseMe on Twitter
Bookmark the DoseMe Blog
Visit the DoseMe Newsroom
Contact DoseMe
About DoseMe
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPPA complaint and is the only Bayesian dosing platform to be HITRUST CSF R2 certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories